好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Conversational Agent for Early Diagnosis of Alzheimer’s Disease and Related Dementias (ADRD): A Pilot Study
Aging, Dementia, and Behavioral Neurology
P7 - Poster Session 7 (8:00 AM-9:00 AM)
13-009

To evaluate whether a voice-interactive conversational agent powered by a large language model (LLM) can systematically elicit diagnostically relevant narratives from patients with suspected Alzheimer's disease and related dementias (ADRD) and informants, comparable to specialist-conducted interviews.

 

Early ADRD diagnosis requires comprehensive patient histories, yet time constraints often limit thorough symptom exploration, particularly outside specialty memory clinics with wait times exceeding one year. We developed a conversational agent to conduct structured interviews systematically covering approximately 70 symptoms across cognitive, behavioral, motor, and functional domains recommended by dementia specialists for assessment.

 

We conducted a within-subjects pilot study with 25 adults with suspected ADRD from a cognitive neurology clinic. Each participant completed both an agent-led interview and a separate clinician interview blinded to the agent interview. Both interviews were recorded and transcribed. Two dementia specialists pre-specified 32 high-yield symptoms from those elicited by the agent, further refined with clinic leadership to 21 core symptoms important for diagnosis or management. Symptoms were labeled in the agent and clinician transcripts by two annotators through consensus, with the clinician used as the benchmark. We evaluated symptom detection using sensitivity and specificity analyses, systematic coverage, ambiguity rates, and user experience surveys (n=19).

Participants: mean age 72±9.8 years; 67% female; 77% White, 20% Black, 3% Asian. The agent achieved 82% sensitivity (95% CI: 74-87%) and 91% specificity (95% CI: 84-95%) for symptom detection. Agent interviews showed more systematic coverage (median per-symptom not-discussed rate: 9.1% vs 22.7% for clinicians; p<0.01). Ambiguity rates were comparable (13.6% agent vs 17.6% clinician; p=0.064). User satisfaction was high; patients provided longer responses to the agent (39.5 vs 13.1 words/utterance).

LLM-based conversational agents can systematically elicit complex ADRD symptoms with performance comparable to specialists, potentially serving as structured front-end tools to aid clinicians with diagnostic efficiency and increasing access.
Authors/Disclosures
Andrew Breithaupt, MD (Emory Goizueta Brain Health Institute)
PRESENTER
The institution of Dr. Breithaupt has received research support from AAN (Research Training Scholarship). The institution of Dr. Breithaupt has received research support from National Institute on Aging. Dr. Breithaupt has received intellectual property interests from a discovery or technology relating to health care. Dr. Breithaupt has received personal compensation in the range of $500-$4,999 for serving as a Consultant (labeling data) with University of California Berkeley.
Brent D. Nelson, DO Dr. Nelson has nothing to disclose.
James D. Finch, PhD Dr. Finch has received personal compensation for serving as an employee of PRGX.
Bryan Choi, MD, PhD Dr. Choi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Third Rock Ventures. Dr. Choi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biodexa Pharmaceuticals.
Oz A. Alon Mr. Alon has nothing to disclose.
Jeanne M. Powell (Emory University) Miss Powell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant/Software Engineer with Georgia State University.
Howard J. Rosen, MD (UCSF) Dr. Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly . Dr. Rosen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alector. The institution of Dr. Rosen has received research support from NIH. The institution of Dr. Rosen has received research support from State of CA. Dr. Rosen has a non-compensated relationship as a Consultant with Prevail Therapeutics that is relevant to AAN interests or activities. Dr. Rosen has a non-compensated relationship as a consultant with Alchemab that is relevant to AAN interests or activities.
Allan I. Levey, MD, PhD (Dept of Neurology Emory University) Dr. Levey has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genuv. Dr. Levey has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cognito Therapeutics. Dr. Levey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Levey has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Karuna Pharmaceuticals. Dr. Levey has received stock or an ownership interest from NextSense. The institution of Dr. Levey has received research support from NIH. The institution of Dr. Levey has received research support from Biogen. The institution of Dr. Levey has received research support from Esai. The institution of Dr. Levey has received research support from AAN. The institution of Dr. Levey has received research support from State of Georgia. The institution of Dr. Levey has received research support from Novartis. The institution of Dr. Levey has received research support from Genentech. Dr. Levey has received intellectual property interests from a discovery or technology relating to health care. Dr. Levey has received personal compensation in the range of $500-$4,999 for serving as a NAPA Avisory Committee Co-Chair with US Dept of Health and Human Services.
James J. Lah, MD, PhD (Emory Brain Health Center) Dr. Lah has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche Diagnostics. The institution of Dr. Lah has received research support from Roche.
Nayoung Choi, PhD Mrs. Choi has nothing to disclose.